common.study.topics.clinical

Triple Combination Therapy in High Risk Crohn's Disease (CD)

common.study.values.description

Triple Combination Therapy in High Risk Crohn's Disease (CD)

The purpose of this study is to determine the effect of triple combination therapy with an anti-integrin (vedolizumab intravenous [IV]), a tumor necrosis factor (TNF) antagonist (adalimumab subcutaneously [SC]), and an immunomodulator (oral methotrexate) on endoscopic remission in participants with newly-diagnosed CD stratified at higher risk for complications.

common.study.values.location

participant.ui.study.affiliations-map.online-study.header-virtual

participant.ui.study.affiliations-map.online-study.text

participant.ui.study.affiliations-map.legend.locations participant.ui.study.affiliations-map.legend.selected

common.study.values.methods

Pharmaceutical medication involved common.study.methods.has-drugs-yes
Recruiting patients only common.study.methods.is-healthy-yes

Drug - Vedolizumab

Vedolizumab intravenous infusion.

Drug - Adalimumab

Adalimumab injection for subcutaneous use.

Drug - Methotrexate

Methotrexate oral tablets.

participant.views.study.view.additional

participant.views.study.view.scientific-title

An Open-Label, Phase 4 Study to Evaluate the Efficacy and Safety of Triple Combination Therapy With Vedolizumab IV, Adalimumab SC, and Oral Methotrexate in Early Treatment of Subjects With Crohn's Disease Stratified at Higher Risk for Developing Complications

common.study.values.clinical-trial-id

NCT02764762

participant.views.study.view.id

oeEXWd